论文部分内容阅读
本文对１１６例肺癌病人同时测定血清中ＣＹＦＲＡ２１—１和ＮＳＥ水平，并与健康人及肺部良性疾病作对照。对其中２０例ＮＳＣＬＣ患者血清ＣＹＦＲＡ２１—１水平在治疗过程中连续观察。结果肺癌患者在治疗前血清ＣＹＦＲＡ２１—１水平明显高于ＢＰＤ组（Ｐ＜０．０１）及正常对照组（Ｐ＜０．０１）。在肺癌组，血清ＣＹＦＲＡ２１—１升高主要在ＮＳＣＬＣ组，阳性率为７２．７３％、ＳＱＣ组为７９．２０％、ＡＤＥ组为６０．１３％，ＬＣＣ组为５０％，均高于ＳＣＬＣ组（１６．６７％）。ＮＳＣＬＣ组血清ＣＹＦＲＡ２１—１与肿瘤分期是正相关。血清ＮＳＥ水平升高以ＳＣＬＣ为主阳性率６６．６７％，高于ＮＳＣＬＣ组２７．２８％（Ｐ＜０．０１）。联合检测血清ＣＹＦＲＡ２１—１和ＮＳＥ可提高整体肺癌的阳性诊断率，从而提高早期诊断。临床上连续动态监测血清ＣＹＦＲＡ２１—１水平对ＮＳＣＬＣ特别是ＳＱＣ的进程、疗效及预后判断有一定价值
In this paper, serum CYFRA21-1 and NSE levels were measured simultaneously in 116 lung cancer patients and compared with healthy individuals and benign lung diseases. The serum CYFRA21-1 levels in 20 NSCLC patients were continuously observed during the course of treatment. Results Serum CYFRA21-1 levels in patients with lung cancer before treatment were significantly higher than those in BPD group (P<0.01) and normal control group (P<0.01). In the lung cancer group, the increase of serum CYFRA21-1 was mainly in the NSCLC group, with a positive rate of 72.73%, 79.20% in the SQC group, 60.13% in the ADE group, and 50% in the LCC group, both higher than the SCLC group. (16.67%). Serum CYFRA21-1 in NSCLC group was positively correlated with tumor stage. The increase of serum NSE level was mainly positive for SCLC, which was 66.67%, which was higher than 27.28% for NSCLC group (P<0.01). Combined detection of serum CYFRA21-1 and NSE can improve the overall rate of positive diagnosis of lung cancer, thereby improving early diagnosis. Clinical continuous monitoring of serum CYFRA21-1 level has certain value in the progress, efficacy and prognosis of NSCLC, especially SQC.